li001

Results from a phase 1/1b study suggest that combining pembrolizumab (Keytruda) with ficerafusp alfa (BCA101) may improve outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), particularly those with HPV-negative disease. Ficerafusp alfa is a novel antibody designed to block both EGFR and TGF-β, two pathways linked to treatment resistance. […]

New analyses from the phase 3 EPCORE FL-1 trial showed that adding epcoritamab (Epkinly) to lenalidomide and rituximab provides significantly better outcomes than lenalidomide and rituximab alone for patients with relapsed or refractory follicular lymphoma. Earlier results showed the triplet reduced the risk of disease progression or death by 79%, with an overall response rate

A phase 1b/2 study found that adding the IDH1 inhibitor ivosidenib to the standard combination of venetoclax and azacitidine produced deep and durable responses in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) who were not candidates for intensive chemotherapy. The trial enrolled 40 patients with a median age of 72 years. Patients received

A large real-world study found that zanubrutinib (Brukinsa) was associated with better outcomes than acalabrutinib (Calquence) in patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers analyzed insurance claims data from nearly 16,800 patients, including 5,819 treated with zanubrutinib and 10,969 treated with acalabrutinib. Patient characteristics were similar between the

Researchers tested an existing cancer drug, panitumumab (Vectibix), in a rare and aggressive kidney cancer called SMARCB1-deficient renal medullary carcinoma. Because the drug is already approved for other cancers, they were able to quickly run a multi-region study in North America and Europe. In 26 heavily pretreated patients, the results were stronger than expected. About